Comparison Overview

bioMérieux

VS

CSL

bioMérieux

100, Allée Louis Pasteur, Marcy-l'Étoile, 69280, FR
Last Update: 2026-04-01
View Profile
Between 750 and 799
https://www.biomerieux.com

A family-owned company, bioMérieux has grown to become a world leader in the field of in vitro diagnostics. Our entrepreneurial adventure, begun over a century ago, is driven by an unrelenting commitment to improve public health worldwide. Since 1963, we've been paving the way in the field of in vitro diagnostics and have contributed greatly to improving public health and making the world a healthier place. The solutions that our teams imagine, develop and manufacture are key to enable healthcare professionals and industry players to make confident decisions to improve patient outcome and ensure consumer safety.

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 12,827
Subsidiaries: 6
12-month incidents
0
Known data breaches
0
Attack type number
1
View Profile

CSL

655 Elizabeth St, Melbourne, 3000, AU
Last Update: 2026-04-02
Between 800 and 849
https://www.csl.com/

CSL is a leading global biopharma company with a dynamic portfolio of lifesaving medicines, including those that treat haemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency, dialysis and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our businesses, CSL Behring, CSL Seqirus, and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 29,000+ people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. See our community guidelines: https://bit.ly/3Bs17Ra

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 23,312
Subsidiaries: 1
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/biomerieux.jpeg
bioMérieux
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/csl.jpeg
CSL
—
ISO 27001
ISO 27001 certification not verified
Not verified
—
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
—
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
—
GDPR
GDPR certification not verified
Not verified
—
PCI DSS
PCI DSS certification not verified
Not verified
—
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
bioMérieux
100%
Compliance Rate
0/4 Standards Verified
CSL
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for bioMérieux in 2026.

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for CSL in 2026.

Incident History — bioMérieux (X = Date, Y = Severity)

bioMérieux cyber incidents detection timeline including parent company and subsidiaries

Incident History — CSL (X = Date, Y = Severity)

CSL cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/biomerieux.jpeg
bioMérieux
Incidents

Date Detected: 6/2023
Type:Vulnerability
Attack Vector: Unauthorized Access
Blog: Blog
https://images.rankiteo.com/companyimages/csl.jpeg
CSL
Incidents

No Incident

FAQ

CSL company demonstrates a stronger AI Cybersecurity Score compared to bioMérieux company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

bioMérieux company has historically faced a number of disclosed cyber incidents, whereas CSL company has not reported any.

In the current year, CSL company and bioMérieux company have not reported any cyber incidents.

Neither CSL company nor bioMérieux company has reported experiencing a ransomware attack publicly.

Neither CSL company nor bioMérieux company has reported experiencing a data breach publicly.

Neither CSL company nor bioMérieux company has reported experiencing targeted cyberattacks publicly.

bioMérieux company has disclosed at least one vulnerability, while CSL company has not reported such incidents publicly.

Neither bioMérieux nor CSL holds any compliance certifications.

Neither company holds any compliance certifications.

bioMérieux company has more subsidiaries worldwide compared to CSL company.

CSL company employs more people globally than bioMérieux company, reflecting its scale as a Biotechnology Research.

Neither bioMérieux nor CSL holds SOC 2 Type 1 certification.

Neither bioMérieux nor CSL holds SOC 2 Type 2 certification.

Neither bioMérieux nor CSL holds ISO 27001 certification.

Neither bioMérieux nor CSL holds PCI DSS certification.

Neither bioMérieux nor CSL holds HIPAA certification.

Neither bioMérieux nor CSL holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

A vulnerability was found in Nothings stb up to 1.26. Impacted is the function stbtt_InitFont_internal in the library stb_truetype.h of the component TTF File Handler. Performing a manipulation results in out-of-bounds read. Remote exploitation of the attack is possible. The exploit has been made public and could be used. The vendor was contacted early about this disclosure but did not respond in any way.

Published
Date
2026-04-01
Updated
Date
2026-04-01
Risk Information
cvss2
Base: 5.0
Severity: LOW
AV:N/AC:L/Au:N/C:N/I:N/A:P
cvss3
Base: 4.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:U/C:N/I:N/A:L
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:P/VC:N/VI:N/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

V-SFT versions 6.2.10.0 and prior contain an out-of-bounds read in VS6ComFile!get_macro_mem_COM. Opening a crafted V7 file may lead to information disclosure from the affected product.

Published
Date
2026-04-01
Updated
Date
2026-04-01
Risk Information
cvss3
Base: 7.8
Severity: LOW
CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H
cvss4
Base: 8.4
Severity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

V-SFT versions 6.2.10.0 and prior contain a stack-based buffer overflow in VS6ComFile!CSaveData::_conv_AnimationItem. Opening a crafted V7 file may lead to arbitrary code execution on the affected product.

Published
Date
2026-04-01
Updated
Date
2026-04-01
Risk Information
cvss3
Base: 7.8
Severity: LOW
CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H
cvss4
Base: 8.4
Severity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

V-SFT versions 6.2.10.0 and prior contain an out-of-bounds read vulnerability in VS6MemInIF!set_temp_type_default. Opening a crafted V7 file may lead to information disclosure from the affected product.

Published
Date
2026-04-01
Updated
Date
2026-04-01
Risk Information
cvss3
Base: 7.8
Severity: LOW
CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H
cvss4
Base: 8.4
Severity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References
Description

V-SFT versions 6.2.10.0 and prior contain an out-of-bounds read vulnerability in VS6ComFile!load_link_inf. Opening a crafted V7 file may lead to information disclosure from the affected product.

Published
Date
2026-04-01
Updated
Date
2026-04-01
Risk Information
cvss3
Base: 7.8
Severity: LOW
CVSS:3.1/AV:L/AC:L/PR:N/UI:R/S:U/C:H/I:H/A:H
cvss4
Base: 8.4
Severity: LOW
CVSS:4.0/AV:L/AC:L/AT:N/PR:N/UI:A/VC:H/VI:H/VA:H/SC:N/SI:N/SA:N/E:X/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
References